PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Metolazone - Hypertension

PAD Profile : Metolazone - Hypertension

Brand Names Include :
Xaqua

Traffic Light Status

Status 1 of 1.

Status :
Non Formulary
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
09 November 2022
Surrey Heartlands Medicines Safety Committee (MSC)

Although there may have been historic prescribing of metolazone for hypertension in parts of Surrey, metolazone has not been formally assessed for this indication in Surrey Heartlands.  Prescribing for hypertension should be in line with NICE NG136 whilst the local Surrey Heartlands hypertension guidelines are being updated (https://surreyccg.res-systems.net/PAD/Guidelines/Detail/4397)

Where metolozone is being prescribed, please take note of the important safety information below:

When initiating patients on metolazone the licensed, branded Xaqua preparation should be prescribed.

Any switch between products should take into account the difference in bioavailability between Xaqua and other available unlicensed products.

Switching from the unlicensed (imported) product to Xaqua may require a reduction in dose by half, or for the same dose to be used but adjust the frequency from daily to alternate days.

The tablets have a single score-line and can be divided into equal halves.

Update March 2023:

  • Refer any patients who are taking unlicensed metolazone and have not been reviewed to the prescribing specialist for review and consideration for switching to the licensed product Xaqua

Associated BNF Codes

02. Cardiovascular System
02.02.01. Thiazides and related diuretics
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More